PFDN6 and acute lymphoblastic leukemia: Additionally, low mRNA levels of PFDN6 were detected in bone marrow samples from high-risk cases of pediatric acute lymphoblastic leukemia compared with the low risk and control healthy groups, suggesting that PFDN6 may be a predictive and treatment biomarker of pediatric acute lymphoblastic leukemia (Dehghan-Nayeri et al., 2017).